201 related articles for article (PubMed ID: 25695449)
1. The impact of neoadjuvant hedgehog inhibitor therapy on the surgical treatment of extensive basal cell carcinoma.
Ching JA; Curtis HL; Braue JA; Kudchadkar RR; Mendoza TI; Messina JL; Cruse CW; Smith DJ; Harrington MA
Ann Plast Surg; 2015 Jun; 74 Suppl 4():S193-7. PubMed ID: 25695449
[TBL] [Abstract][Full Text] [Related]
2. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY
J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884
[TBL] [Abstract][Full Text] [Related]
3. Vismodegib for periocular and orbital basal cell carcinoma.
Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
[TBL] [Abstract][Full Text] [Related]
4. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
5. Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC).
Kwon GP; Ally MS; Bailey-Healy I; Oro AE; Kim J; Chang AL; Aasi S; Tang JY
J Am Acad Dermatol; 2016 Jul; 75(1):213-5. PubMed ID: 27317518
[No Abstract] [Full Text] [Related]
6. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
7. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
8. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
Meani RE; Lim SW; Chang AL; Kelly JW
Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
[TBL] [Abstract][Full Text] [Related]
9. Induction Hedgehog pathway inhibition followed by combined-modality radiotherapy for basal cell carcinoma.
Raleigh DR; Algazi A; Arron ST; Neuhaus IM; Yom SS
Br J Dermatol; 2015 Aug; 173(2):544-6. PubMed ID: 25702621
[TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing of the basal cell carcinoma miRNome and a description of novel microRNA candidates under neoadjuvant vismodegib therapy: an integrative molecular and surgical case study.
Sand M; Bechara FG; Gambichler T; Sand D; Friedländer MR; Bromba M; Schnabel R; Hessam S
Ann Oncol; 2016 Feb; 27(2):332-8. PubMed ID: 26578727
[TBL] [Abstract][Full Text] [Related]
11. Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.
Calzavara Pinton P; Licitra L; Peris K; Santoro A; Ascierto PA
Future Oncol; 2015; 11(9):1429-35. PubMed ID: 25952787
[TBL] [Abstract][Full Text] [Related]
12. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
Lyseng-Williamson KA; Keating GM
Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
[TBL] [Abstract][Full Text] [Related]
13. Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC.
Ali FR; Lear JT
Br J Dermatol; 2013 Jul; 169(1):53-7. PubMed ID: 23488543
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of adjunctive therapies post hedgehog inhibitors in the management of locally advanced basal cell carcinoma: A systematic review and pooled analysis.
Patel A; Kim JS; Liss J; Howard L; Jung SH; Kheterpal M
Dermatol Ther; 2021 Nov; 34(6):e15172. PubMed ID: 34676633
[TBL] [Abstract][Full Text] [Related]
15. Vismodegib in the treatment of advanced BCC.
O'Kane GM; Lyons T; McDonald I; Mulligan N; Moloney FJ; Murray D; Kelly CM
Ir Med J; 2014; 107(7):215-6. PubMed ID: 25226719
[TBL] [Abstract][Full Text] [Related]
16. Hedgehog inhibitors with and without adjunctive therapy in treatment of locally advanced basal cell carcinoma.
Patel AD; Ravichandran S; Kheterpal M
Int J Dermatol; 2022 Jan; 61(1):118-124. PubMed ID: 34423419
[TBL] [Abstract][Full Text] [Related]
17. Lichenoid reaction as a potential immune response marker of intratreatment histological response during successful vismodegib treatment for a giant basal cell carcinoma.
Fosko SW; Chu MB; Mattox AR; Richart JM; Burkemper NM; Slutsky JB
Dermatol Ther; 2015; 28(6):359-62. PubMed ID: 26114264
[TBL] [Abstract][Full Text] [Related]
18. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.
Mathis J; Doerr T; Lin E; Ibrahim SF
Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344
[TBL] [Abstract][Full Text] [Related]
19. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
Cirrone F; Harris CS
Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
[TBL] [Abstract][Full Text] [Related]
20. Treatment of margin positive basal cell carcinoma with vismodegib: case report and consideration of treatment options and their implications.
Bayers S; Kapp DL; Beer KR; Slavin B
J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s147-50. PubMed ID: 24085060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
